Skip to main content

Emergent BioSolutions

Combating The Opioid Overdose Crisis

Emergent BioSolutions Completes Acquisition of Adapt Pharma and its Flagship Product NARCAN® (naloxone HCI) Nasal Spray

Emergent BioSolutions Completes Acquisition of Specialty Vaccines Company PaxVax

Celebrating 20 Years of People, Products, and Possibilities

Developing Products that Address Emerging Infectious Diseases

Emergent BioSolutions Initiates Phase 1 Clinical Study of Zika Virus Immune Globulin Therapeutic

Expanding our Manufacturing Capabilities

Emergent BioSolutions Announces $50 Million Expansion of Baltimore Fill/Finish Facility

Explore more stories Scroll down